Skip to main content
Exclusive Savings: Take 10% OFF All Cenmed Products | Upgrade Your Lab For Less Shop Now
US English

ALADDIN SCIENTIFIC

Vicagrel

Vicagrel is a potent, safe and orally active antiplatelet agent, which works by irreversibly inhibiting P2Y12 receptor. Vicagrel can be used for the research of blood clots in coronary artery disease, peripheral vascular disease, and...

Description

Vicagrel is a potent, safe and orally active antiplatelet agent, which works by irreversibly inhibiting P2Y12 receptor. Vicagrel can be used for the research of blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.In VitroVicagrel (compound 9a) (20 μM, 30 min) activates production of the active metabolite from in vitro rat liver microsomal. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoVicagrel (compound 9a) (oral, 3 mg/kg) has inhibitory effect on ADP-induced platelet aggregation in rats . Vicagrel (oral, 1.14 mg/mL, 0-24 h) has giood preliminary pharmacokinetic with high bioavailability and low clinically effective dose . Vicagrel (oral, 5 g/kg, single, for 14 days) has low dose-related toxicity in mouse . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Wistar rats (200−250 g) Dosage: 3 mg/kg Administration: oral Result: Inhibitied platelet aggregation by ADP-induced in rats. Animal Model: SD male rats Dosage: 1.14 mg/mL Administration: oral, 0-24 h Result: Could be readily converted into clopidogrel thiolactone and had high bioavailability. Animal Model: Mice Dosage: 5 g/kg Administration: oral, single, for 14 days Result: Had very low acute toxicity.Form:Solid


Specifications & Purity: Vicagrel is a potent, safe and orally active antiplatelet agent, which works by irreversibly inhibiting P2Y12 receptor. Vicagrel can be used for the research of blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.In VitroVicagrel (compound 9a) (20 μM, 30 min) activates production of the active metabolite from in vitro rat liver microsomal. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoVicagrel (compound 9a) (oral, 3 mg/kg) has inhibitory effect on ADP-induced platelet aggregation in rats . Vicagrel (oral, 1.14 mg/mL, 0-24 h) has giood preliminary pharmacokinetic with high bioavailability and low clinically effective dose . Vicagrel (oral, 5 g/kg, single, for 14 days) has low dose-related toxicity in mouse . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Wistar rats (200−250 g) Dosage: 3 mg/kg Administration: oral Result: Inhibitied platelet aggregation by ADP-induced in rats. Animal Model: SD male rats Dosage: 1.14 mg/mL Administration: oral, 0-24 h Result: Could be readily converted into clopidogrel thiolactone and had high bioavailability. Animal Model: Mice Dosage: 5 g/kg Administration: oral, single, for 14 days Result: Had very low acute toxicity.Form:Solid


Grade: Moligand™


Molecular Formula: C18H18ClNO4S


Molecular Weight: 379.86


PubChem CID: 53378151


Isomeric SMILES: CC(=O)OC1=CC2=C(S1)CCN(C2)[C@@H](C3=CC=CC=C3Cl)C(=O)OC


Storage Temperature: Store at -20°C


Shipped in: Ice chest + Ice pads


Specifications
UPC:
51111840
Weight:
1.09 Ounces
HazmatClass:
Yes
Quantity:
1
Unit of Measurement:
EA
WeightUOM:
LB
MPN:
V647442-1mg
Country of Origin:
China
CAS:
1314081-53-2
Product Size:
1mg
Harmonized Tariff Code:
2931.90.90
Catalog No. C008B-269108
Price: $259.17
List Price: $287.97
  • Guaranteed quality & reliable delivery
  • Shipping Lead-Time: 14-21 Days
Adding to cart… The item has been added
Request a Quote

Enjoy exclusive benefits, including discounted pricing on bulk orders, by opening a Cenmed Business Account. Learn More.